M.J. Millward

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

Richard Kefford, Hendrik‐Tobias Arkenau, Michael P. Brown et al. · Journal of Clinical Oncology · 2010 · 274 citations

Medicine, Oncology, Pharmacology +17

Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

Stephen Clarke, R. Abratt, L. Goedhals et al. · Annals of Oncology · 2002 · 122 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

John Zalcberg, M.J. Millward, J. Bishop et al. · Journal of Clinical Oncology · 1998 · 90 citations

Medicine, Oncology, Pharmacology +15

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

M.J. Millward, B.M.J. Cantwell, N.C. Munro et al. · British Journal of Cancer · 1993 · 89 citations · Full text

Medicine, Oncology, Pharmacology +9

Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia–Pacific region

Thomas C. Putti, Ka‐Fai To, H C Hsu et al. · Histopathology · 2002 · 65 citations

Medicine, Oncology, Otolaryngology +13